Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Original Article by Jacob Webster | Business Day | 4 March 2026
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
More Posts
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...
Momentum Group Posts Record Earnings
Momentum Group has posted record earnings, with normalised headline earnings up 13% to R7.06bn – beating its R7bn Impact target a year early.
Read more...
Sanlam Writes Down AfroCentric to Nil but Won’t Sell
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Read more...